Identification of polymerase and processivity inhibitors of vaccinia DNA synthesis using a stepwise screening approach

Antiviral Research

Volumn 80, Issue 2, 2008, Pages 114-123

  Silverman, Janice Elaine Y ^a   Ciustea, Mihai ^a   Shudofsky, Abigail M Druck ^b   Bender, Florent ^a   Shoemaker, Robert H ^c   Ricciardi, Robert P ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antiviral inhibitors; DNA polymerase; High throughput screening; Poxvirus; Processivity factor; Rapid plate assay; Smallpox; Vaccinia virus

Indexed keywords

DNA POLYMERASE; ENZYME INHIBITOR; FENTICLOR; NSC 123526; NSC 55636; PROTEIN A20; PROTEIN D4; PROTEIN E9; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ARTICLE; ASSAY; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; SMALLPOX VIRUS; VACCINIA VIRUS; VIRUS CULTURE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; DNA-DIRECTED DNA POLYMERASE; DRUG EVALUATION, PRECLINICAL; HUMANS; NUCLEIC ACID SYNTHESIS INHIBITORS; VACCINIA; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS REPLICATION;

POXVIRIDAE; VACCINIA VIRUS; VARIOLA; VARIOLA VIRUS;

EID: 53249121830     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.05.010     Document Type: Article

References (66)

1. Afonso C.L., Tulman E.R., Lu Z., Zsak L., Sandybaev N.T., Kerembekova U.Z., Zaitsev V.L., Kutish G.F., and Rock D.L. The genome of camelpox virus. Virology 295 (2002) 1-9
2. Andrei G., Gammon D.B., Fiten P., De Clercq E., Opdenakker G., Snoeck R., and Evans D.H. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol. 80 (2006) 9391-9401
3. Beadle J.R., Hartline C., Aldern K.A., Rodriguez N., Harden E., Kern E.R., and Hostetler K.Y. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46 (2002) 2381-2386
4. Beaud G. Vaccinia virus DNA replication: a short review. Biochimie 77 (1995) 774-779
5. Bougie I., and Bisaillon M. The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J. Biol. Chem. 279 (2004) 22124-22130
6. Brier S., Lemaire D., Debonis S., Forest E., and Kozielski F. Identification of the protein binding region of S-trityl-l-cysteine, a new potent inhibitor of the mitotic kinesin Eg5. Biochemistry 43 (2004) 13072-13082
7. Chaudhuri M., and Parris D.S. Evidence against a simple tethering model for enhancement of herpes simplex virus DNA polymerase processivity by accessory protein UL42. J. Virol. 76 (2002) 10270-10281
8. Chen X., Lin K., and Ricciardi R.P. Human Kaposi's sarcoma herpesvirus processivity factor-8 functions as a dimer in DNA synthesis. J. Biol. Chem. 279 (2004) 28375-28386
9. Chen Y., Ciustea M., and Ricciardi R.P. Processivity factor of KSHV contains a nuclear localization signal and binding domains for transporting viral DNA polymerase into the nucleus. Virology 340 (2005) 183-191
10. Chen Z., Earl P., Americo J., Damon I., Smith S.K., Zhou Y.H., Yu F., Sebrell A., Emerson S., Cohen G., Eisenberg R.J., Svitel J., Schuck P., Satterfield W., Moss B., and Purcell R. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 1882-1887
11. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 55 (2002) 1-13
12. De Silva F.S., and Moss B. Vaccinia virus uracil DNA glycosylase has an essential role in DNA synthesis that is independent of its glycosylase activity: catalytic site mutations reduce virulence but not virus replication in cultured Cells. J. Virol. 77 (2003) 159-166
13. Delahanty J.N., Evans J.C., Rowlands C.C., Barratt M.D., and Pendlington R.U. Radicals involved in photoallergen/protein interactions. Free Radic. Biol. Med. 7 (1989) 231-236
14. Dorjsuren D., Burnette A., Gray G.N., Chen X., Zhu W., Roberts P.E., Currens M.J., Shoemaker R.H., Ricciardi R.P., and Sei S. Chemical library screen for novel inhibitors of Kaposi's sarcoma-associated herpesvirus processive DNA synthesis. Antiviral Res. 69 (2006) 9-23
15. Ellison K.S., Peng W., and McFadden G. Mutations in active-site residues of the uracil-DNA glycosylase encoded by vaccinia virus are incompatible with virus viability. J. Virol. 70 (1996) 7965-7973
16. Hamilton M.D., Nuara A.A., Gammon D.B., Buller R.M., and Evans D.H. Duplex strand joining reactions catalyzed by vaccinia virus DNA polymerase. Nucleic Acids Res. 35 (2007) 143-151
17. Hindsén M., Zimerson E., and Bruze M. Photoallergic contact dermatitis from ketoprofen in southern Sweden. Contact Dermatitis 54 (2006) 150-157
18. Hingorani M.M., and O'Donnell M. DNA polymerase structure and mechanisms of action. Curr. Org. Chem. 4 (2000) 887-913
19. Holzer G.W., Mayrhofer J., Gritschenberger W., and Falkner F.G. Dominant negative selection of vaccinia virus using a thymidine kinase/thymidylate kinase fusion gene and the prodrug azidothymidine. Virology 337 (2005) 235-241
20. Hugo W.B., and Bloomfield S.F. Studies on the mode of action of the phenolic antibacterial agent fentichlor against Staphylococcus aureus and Escherichia coli.II. The effects of fentichlor on the bacterial membrane and cytoplasmic constituents of the cell. J. Appl. Bacteriol. 34 (1971) 569-578
21. Hugo W.B., and Bloomfield S.F. Studies on the mode of action of the phenolic antibacterial agent fentichlor against Staphylococcus aureus and Escherichia coli.I. The adsorption of fentichlor by bacterial cell and its antibacterial activity. J. Appl. Bacteriol. 34 (1971) 557-567
22. Hugo W.B., and Bloomfield S.F. Studies on the mode of action of the phenolic antibacterial agent fentichlor against Staphylococcus aureus and Escherichia coli.III. The effect of fentichlor on the metabolic activities of Staphylococcus areus and Escherichia coli. J. Appl. Bacteriol. 34 (1971) 579-591
23. Ishii K., and Moss B. Mapping interaction sites of the A20R protein component of the vaccinia virus DNA replication complex. Virology 303 (2002) 232-239
24. Jeruzalmi D., O'Donnell M., and Kuriyan J. Clamp loaders and sliding clamps. Curr. Opin. Struc. Biol. 12 (2002) 217-224
25. Kit S., Dubbs D.R., and Piekarski L.J. Enhanced thymidine phosphorylating activity of mouse fibroblasts (strain LM) following vaccinia infection. Biochem. Biophys. Res. Commun. 8 (1962) 72-75
26. Klemperer N., McDonald W., Boyle K., Unger B., and Traktman P. The A20R protein is a stoichiometric component of the processive form of vaccinia virus DNA polymerase. J. Virol. 75 (2001) 12298-12307
27. Kornbluth R.S., Smee D.F., Sidwell R.W., Snarsky V., Evans D.H., and Hostetler K.Y. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob. Agents Chemother. 50 (2006) 4038-4043
28. Kuriyan J., and O'Donnell M. Sliding clamps of DNA polymerases. J. Mol. Biol. 234 (1993) 915-925
29. Lane J.M., and Millar J.D. Risks of smallpox vaccination complications in the United States. Am. J. Epidemiol. 93 (1971) 238-240
30. Lane J.M., Ruben F.L., Neff J.M., and Millar J.D. Complications of smallpox vaccination, 1968. N. Engl. J. Med. 281 (1969) 1201-1208
31. Lane J.M., Ruben F.L., Neff J.M., and Millar J.D. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J. Infect. Dis. 122 (1970) 303-309
32. Lane H.C., Montagne J.L., and Fauci A.S. Bioterrorism: a clear and present danger. Nat. Med. 7 (2001) 1271-1273
33. Li A.S.W., and Chignell C.F. Generation of free-radicals during the photolysis of the photoallergens bithionol and fentichlor-a spin trapping study. Environ. Health Perspect. 75 (1987) 131
34. Lin K., and Ricciardi R.P. The 41-kDa protein of human herpesvirus 6 specifically binds to viral DNA polymerase and greatly increases DNA synthesis. Virology 250 (1998) 210-219
35. Lin K., and Ricciardi R.P. A rapid plate assay for the screening of inhibitors against herpesvirus DNA polymerases and processivity factors. J. Virol. Methods 88 (2000) 219-225
36. Lin K., Dai C.Y., and Ricciardi R.P. Cloning and functional analysis of Kaposi's sarcoma-associated herpesvirus DNA polymerase and its processivity factor. J. Virol. 72 (1998) 6228-6232
37. Magee W.C., Hostetler K.Y., and Evans D.H. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob. Agents Chemother. 49 (2005) 3153-3162
38. McCraith S., Holtzman T., Moss B., and Fields S. Genome-wide analysis of vaccinia virus protein-protein interactions. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4879-4884
39. McDonald W.F., and Traktman P. Vaccinia virus DNA polymerase. In vitro analysis of parameters affecting processivity. J. Biol. Chem. 269 (1994) 31190-31197
40. Millns A.K., Carpenter M.S., and DeLange A.M. The vaccinia virus-encoded uracil DNA glycosylase has an essential role in viral DNA replication. Virology 198 (1994) 504-513
41. Moss B. Poxviridae: the viruses and their replication. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields Virology (2001), Lippincott-Raven, Philadelphia 2849-2883
42. Quenelle D.C., Buller R.M., Parker S., Keith K.A., Hruby D.E., Jordan R., and Kern E.R. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 51 (2007) 689-695
43. Quenelle D.C., Prichard M.N., Keith K.A., Hruby D.E., Jordan R., Painter G.R., Robertson A., and Kern E.R. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob. Agents Chemother. 51 (2007) 4118-4124
44. Reeves P.M., Bommarius B., Lebeis S., McNulty S., Christensen J., Swimm A., Chahroudi A., Chavan R., Feinberg M.B., Veach D., Bornmann W., Sherman M., and Kalman D. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med. 11 (2005) 731-739
45. Robbins S.J., Jackson R.J., Fenner F., Beaton S., Medveczky J., Ramshaw I.A., and Ramsay A.J. The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4. Antiviral Res. 66 (2005) 1-7
46. Sbrana E., Jordan R., Hruby D.E., Mateo R.I., Xiao S.Y., Siirin M., Newman P.C., Da Rosa A.P., and Tesh R.B. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 76 (2007) 768-773
47. Scaramozzino N., Sanz G., Crance J.M., Saparbaev M., Drillien R., Laval J., Kavli B., and Garin D. Characterisation of the substrate specificity of homogeneous vaccinia virus uracil-DNA glycosylase. Nucleic Acids Res. 31 (2003) 4950-4957
48. Schmahl H.J., and Hieke E. Separation and identification of some anti-microbials used also in cosmetic products by means of thin-layer chromatography. Fresenius Zeitschrift Fur Analytische Chemie 304 (1980) 398-404
49. Schmahl H.J., and Matissek R. Separation and determination of phenolic anti-microbials from non-emulsified cosmetics containing surfactants. Fresenius Zeitschrift Fur Analytische Chemie 307 (1981) 392-399
50. Schormann N., Grigorian A., Samal A., Krishnan R., DeLucas L., and Chattopadhyay D. Crystal structure of vaccinia virus uracil-DNA glycosylase reveals dimeric assembly. BMC Struct. Biol. 7 (2007) 45
51. Serafimova R., Todorov M., Pavlov T., Kotov S., Jacob E., Aptula A., and Mekenyan O. Identification of the structural requirements for mutagencitiy, by incorporating molecular flexibility and metabolic activation of chemicals. II. General Ames mutagenicity model. Chem. Res. Toxicol. 20 (2007) 662-676
52. Shoemaker R.H., Scudiero D.A., Melillo G., Currens M.J., Monks A.P., Rabow A.A., Covell D.G., and Sausville E.A. Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr. Top Med. Chem. 2 (2002) 229-246
53. Skoufias D.A., DeBonis S., Saoudi Y., Lebeau L., Crevel I., Cross R., Wade R.H., Hackney D., and Kozielski F. S-trityl-l-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. J. Biol. Chem. 281 (2006) 17559-17569
54. Smee D.F., Sidwell R.W., Kefauver D., Bray M., and Huggins J.W. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 46 (2002) 1329-1335
55. St. Clair M.H., Furman P.A., Lubbers C.M., and Elion G.B. Inhibition of cellular alpha and virally induced deoxyribonucleic acid polymerases by the triphosphate of acyclovir. Antimicrob. Agents Chemother. 18 (1980) 741-745
56. Stanitsa E.S., Arps L., and Traktman P. Vaccinia virus uracil DNA glycosylase interacts with the A20 protein to form a heterodimeric processivity factor for the viral DNA polymerase. J. Biol. Chem. 281 (2006) 3439-3451
57. Veselova T.P., Lapteva L.A., and Khrustaleva L.I. Embryotoxic and teratogenic effects of oksid. Veterinariya 8 (1980) 56
58. Vilar S., Santana L., and Uriarte E. Probabilistic neural network model for the in silico evaluation of anti-HIV activity and mechanism of action. J. Med. Chem. 49 (2006) 1118-1124
59. Watson, G., 1973. Biocidal materials containing fentichlor, GB Patent 1308511.
60. Weisshart K., Chow C.S., and Coen D.M. Herpes simplex virus processivity factor UL42 imparts increased DNA-binding specificity to the viral DNA polymerase and decreased dissociation from primer-template without reducing the elongation rate. J. Virol. 73 (1999) 55-66
61. Willer D.O., Mann M.J., Zhang W., and Evans D.H. Vaccinia virus DNA polymerase promotes DNA pairing and strand-transfer reactions. Virology 257 (1999) 511-523
62. Williams A.J., Wernette C.M., and Kaguni L.S. Processivity of mitochondrial DNA polymerase from Drosophila embryos. Effects of reaction conditions and enzyme purity. J. Biol. Chem. 268 (1993) 24855-24862
63. Wodarz D., and Lloyd A.L. Immune responses and the emergence of drug-resistant virus strains in vivo. Proc. Biol. Sci. 271 (2004) 1101-1109
64. Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L., Touchette E., Waller K., Schriewer J., Neyts J., DeClercq E., Jones K., Hruby D., and Jordan R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J. Virol. 79 (2005) 13139-13149
65. Zee-Cheng K.Y., and Cheng C.C. Experimental antileukemic agents. Preparation and structure-activity study of S-tritylcysteine and related compounds. J. Med. Chem. 13 (1970) 414-418
66. Zhang W.D., and Evans D.H. DNA strand exchange catalyzed by proteins from vaccinia virus-infected cells. J. Virol. 67 (1993) 204-212